Broad-Spectrum Antimicrobial Benefits Include 60-Second Kill Time and No Rinse Required
RANCHO CUCAMONGA, CA (Mar 17, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced its PURE® Hard Surface disinfectant (EPA Reg. No. 72977-5-73912) has been added to the U.S. EPA’s List N: Disinfectants for Use Against SARS-CoV-2 (the EPA’s expanded list of disinfectants for use against COVID-19) based on its efficacy against the Human Coronavirus.
PURE’s Chairman and CEO Tom Y. Lee said, “On the heels of our first order to Asia, we are pleased to announce our highly efficacious PURE Hard Surface has been added to the expanded EPA COVID-19 Disinfectants List to help combat the spread of COVID-19.
“Q3 sales of PURE Hard Surface are off to a record start. The increased sales volume includes follow-on orders from existing food service customers and increased distributor sales. Unlike most disinfectants, PURE Hard Surface kills germs in as few as 60 seconds (versus up to 10 minutes for competitors) and does not require rinsing. It is also safe for food contact surfaces and is used by nationwide restaurant chains and QSRs (quick service restaurants).
“PURE Hard Surface is a proven and effective disinfectant solution that is also being used in the U.S. by food transport companies to disinfect refrigerated trucks, by produce processors for disinfecting equipment and by more than 100 food processors/manufactures,” concluded Lee.
Since 2011, the EPA has registered PURE Hard Surface disinfectant to be effective on a wide range of pathogens, including:
Superior Efficacy: Eco-Friendly Sanitization Solution on Hard, Non-Porous, Environmental and Food Contact Surfaces
Mode of Action - How It Works
SDC’s rapid and broad-spectrum efficacy is largely attributed to its dual mechanisms of action and unique characteristics. PURE’s ‘Trojan Horse’ mode of action video is available at https://www.purebio.com/technology/silver-dihydrogen-citrate-sdc.htm.
For more information about SARS-CoV-2, please refer to the CDC website at: https://www.cdc.gov/coronavirus/2019-ncov/. The EPA disinfection list is comprised of the primary product registration number and may be sold under a different brand name. You can identify the product by the three-part EPA registration number. The first two parts match the primary product and the third part represents the distributor ID. SDC3A (EPA Reg. No. 72977-5) is the primary product registered by the EPA and sold under the brand name PURE Hard Surface. ETI H20, INC., the company that holds the aforementioned EPA registration number, is a wholly-owned subsidiary of PURE Bioscience, Inc. When using PURE Hard Surface, follow the label instructions for disinfecting hard, non-porous surfaces against Human Coronavirus. This will ensure an adequate kill step is achieved.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the second fiscal quarter ended January 31, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mark Elliott, VP Finance
PURE Bioscience, Inc.